Progress of pharmacotherapy for myocardial hypertrophy and cardiac remodeling
10.12092/j.issn.1009-2501.2022.04.005
- Author:
Juan PENG
1
;
Yunzeng ZOU
1
;
Ranyi LI
2
;
Linlin FAN
2
;
Xiaoyu LI
2
;
Qianzhou LV
2
Author Information
1. Shanghai Institute of Cardiovascular Disease, Department of Cardiology Zhongshan Hospital, Fudan University
2. Department of Pharmacy, Zhongshan Hospital, Fudan University
- Publication Type:Journal Article
- Keywords:
Cardiac remodeling;
Cardiomyopathy;
Myocardial hypertrophy
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):382-389
- CountryChina
- Language:Chinese
-
Abstract:
Cardiomyopathy is a disease with abnormal myocardial structure and function. For a long time, due to the limited understanding of cardiomyopathies, cardiomyopathies are treated empirically based on symptoms (such as heart failure, arrhythmia, etc.). Over years, with the improvement of diagnosis technology and the discover of disease mechanism, a variety of drugs have been approved, such as tafamidis, patisiran and Inotersen. Many more drugs have completed preliminary safety and efficacy verification and entered Phase III trials. In addition, some cutting-edge technologies are also being developed, such as siRNA drug patisiran, CRISPR/Cas9 gene editing technology drug NTLA-2001, stem cell therapy, etc. This article discusses two cardiac problems that may be caused by cardiomyopathy: myocardial hypertrophy and cardiac remodeling, and introduces the pharmacology and related research of the latest drugs for these diseases.
